Abstract
Purpose
Supplements are commonly used to prevent cardiovascular diseases. Unfortunately, studies on folic acid supplementation have failed to support its benefit with pre-existing cardiovascular disease. Observational data suggest the benefit may be greater for healthy and at-risk individuals, but clinical trials have yet to be presented. The purpose of this paper is to systematically review evidence regarding the effectiveness of folic acid supplementation on homocysteine levels among healthy people who are at risk regarding the primary prevention of heart disease.
Methods
PubMed, Science Direct, COCHRANE Library, and Clinical Trial.gov were searched from the year 2000 to 2015, with manual searches of references list and gray literature. Two investigators were selected to review fair- and good-quality trials that included healthy participants or healthy with risk, measurements of homocysteine levels and trials reporting at least one of the coronary heart diseases as an outcome. Dual quality assessments and data abstraction protocols were established.
Results
There are limited new trials that have been published to show the effectiveness in primary prevention of cardiovascular disease. This limited evidence has given a strong association regarding the effects of folic acid supplementation in reducing homocysteine levels. However, the effectiveness for its role in the primary prevention of a cardiovascular event is still not proven as being beneficial.
Conclusion
Limited evidence supports any benefit from folic acid supplementation for the primary prevention of coronary heart disease. Studies of the combined effect of folic acid with another preventative method of cardiovascular disease will help determine if folic acid supplementation causally reduces the cardiovascular event from the primary level. To prove its effectiveness, future clinical trials need to be performed.
Similar content being viewed by others
References
Abraham JM, Cho L (2010) The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease? J Clin Med 77(12):911–918. doi:10.3949/ccjm.77a.10036
Albert CM, Cook NR, Gaziano JM (2008) Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299:2027–2036
Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C (1994) Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106(1):9–19
Anderson JL, Jensen KR, Carlquist JF, Bair TL, Horne BD, Muhlestein JB (2004) Effect of folic acid fortification of food on homocysteine-related mortality. Am J Med 116(3):158–164
Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG (2001) Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyper homo cyst(e)inaemia in humans. Clin Sci 100(2):161–167
Brustolin S, Giugliani R, Félix TM (2010) Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res 43(1):1–7
Chao CL, Kuo TL, Lee YT (2000) Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation 101(5):485–490
Cui R, Iso H, Date C, Kikuchi S, Tamakoshi A, Japan Collaborative Cohort Study Group (2010) Dietary folate and vitamin B6 and B12 intake in relation to mortality from cardiovascular diseases: Japan Collaborative Cohort Study. Stroke 41:1285–1289
Doshi SN, Mcdowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J (2001) Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 21(7):1196–1202
Horvath B, Szapary L, Debreceni L (2009) Effect of Sclerovit on endothelial dysfunction, hemorheological parameters, platelet aggregation, plasma concentration of homocysteine and progression of atherosclerosis in patients with vascular diseases. Clin Hemorheol Microcirc 42:19–28
Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, Hou FF (2015) Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 313(13):1325–1335
Hwang SY, Siow YL, Au-Yeung KK, House JOK (2011) Folic acid supplementation inhibits NADPH oxidase-mediated superoxide anion production in the kidney. Am J Physiol Renal Physiol 300(1):F189–F198
Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG (2002) Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 282(6):H2167–H2172
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
Mager A, Orvin K, Koren-Morag N, Lev IE, Assali A, Kornowski R, Shohat M, Battler A, Hasdai D (2009) Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease. Am J Cardiol 104(6):745–749
Martí-Carvajal AJ, Sola I, Lathyris D (2015) Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD006612.pub4
Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A (2003) The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr 133:2863–2867
Moher D, Liberati A, Tetzlaff J (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRIsMa statement. Ann Intern Med 151:264–269
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 63:e1–e37
Mora S, Cook N, Buring JE, Ridker PM, Lee IM (2007) Physical activity and reduced risk of cardiovascular events potential mediating mechanisms. Circulation 116(19):2110–2118
Nakano E, Higgins JA, Powers HJ (2001) Folate protects against oxidative modification of human LDL. Br J Nutr 86(6):637–639
Neves MF, Endemann D, Amiri F, Virdis A, Pu Q, Rozen R, Schiffrin EL (2004) Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. J Hypertens 22(5):959–966
Nordrehaug JE, Ueland PM, Kvéle G (1995) Total plasma homocysteine and cardiovascular risk profile. JAMA 274:1526–1533
O’Callaghan P, Meleady R, Fitzgerald T, Graham I (2002) Smoking and plasma homocysteine. Eur Heart J 23(20):1580–1586
Peng HY, Man CF, Xu J, Fan Y (2015) Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. J Zhejiang Univ Sci B 16(1):78–86
Refsum H, Ueland PM, Nygård O, Vollset SE (1998) Homocysteine and cardiovascular disease. Annu Rev Med 49(1):31–62
Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, Gaziano JM (2012) Multivitamins in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA 308(17):1751–1760
Smulders YM, Stehouwer CD (2005) Folate metabolism and cardiovascular disease. Semin Vasc Med 5(2):87–97
Stroes ES, Van Faassen EE, Yo M, Martasek P, Boer P, Govers R, Rabelink TJ (2000) Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 86(11):1129–1134
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage JM, Bowman L, Clarke RJ (2010) Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 303:2486–2494
Verhaar MC, Stroes E, Rabelink TJ (2002) Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 22(1):6–13
Verhoef P, Stampfer MJ, Braunwald E (1997) Homocysteine: a risk factor for coronary artery disease. Heart Dis Textbook Cardiovasc Med: Update 2:1–8
VITATOPS Trial Study Group (2010) B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomized, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9(9):855–865
Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B (2012) Homocysteine level and risk of fracture: a meta-analysis and systematic review. Bone 51(3):376–382
Acknowledgements
We would like to express our special thanks of gratitude to those involved directly and indirectly with the completion of this manuscript, which was undertaken with the hope it can contribute to future knowledge on the subject.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahmood, M.I., Rosli, N.M., Shukor, M.F.A. et al. Effects of folic acid supplementation on homocysteine level as primary prevention of heart disease: a systematic review. J Public Health 23, 387–394 (2015). https://doi.org/10.1007/s10389-015-0691-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10389-015-0691-6